Titlebook: Rare Lymphomas; Martin Dreyling,Michael E. Williams Book 2014 Springer-Verlag Berlin Heidelberg 2014 Malignant Lymphoma.Molecular Pathogen

Blasphemy

口訣

HIV-Associated LymphomasV-related lymphoid hyperplasia of various kind and overt malignant lymphomas. Lymphomas arising in the setting of HIV infection have been subclassified based on their occurrence in immunocompromised individuals, in the setting of HIV exclusively, and those occurring in immunocompetent individuals as

職業(yè)拳擊手

Non-MALT Marginal Zone LymphomaL). Although they share a common cell of origin from the “marginal zone” (MZ), they display different clinical characteristics, reflecting probable biological variations according to the organ. Within the past decade, new data regarding pathogenic mechanisms as well as therapeutic advances have been

免除責任

夾克怕包裹

凝結(jié)劑

Waldenstr?m’s Macroglobulinemiasyndrome of oronasal bleeding, lymphadenopathy, an elevated sedimentation rate, hyperviscosity, normal bone films, cytopenias, and a bone marrow with a predominantly bone marrow infiltrate (Waldenstr?m 1944). The second international workshop on WM attempted to refine the working definition of the d

令人悲傷

Cutaneous T-Cell Lymphomaefinition of additional subtypes of CTCL apart from MF and SS has led to an evolving classification of CTCL over the years, finally settled as the consensus classification of WHO and EORTC in 2005 (Willemze et al. 2005) which was then fully incorporated into the 2008 revised WHO lymphoma classification.

ORBIT

使堅硬

Molecular Genetics of Rare Lymphomass is critically warranted to substantially improve prognosis. This chapter summarizes current concepts of our understanding of the molecular pathogenesis of “rare lymphomas” subtypes. This is exemplified by focusing on selected subtypes, namely, primary mediastinal B-cell lymphoma, Burkitt lymphoma, and mantle cell lymphoma.

Genteel

CNS Lymphomad should be considered backbone of therapy; however, the optimal management of CNSL has not been fully established. For long-term survivors, late neurotoxicity is an important issue, particularly when whole-brain radiotherapy (WBRT) was performed. Whenever possible, patients with CNS involvement of lymphoma should be included in clinical trials.